15 March 2018 - - Waltham, Massachusetts-based global biopharmaceutical services provider Parexel International Corp. has formed an alliance with CHA Medical Group to enhance early phase clinical development in Korea, the company said.
The collaboration is designed to provide biopharmaceutical companies with comprehensive services that leverage Parexel's global clinical research and regulatory expertise with CHA's experience conducting early phase studies in Korea.
Korea's regulatory requirements, modeled after the US Food and Drug Administration, enable sponsors to use the data from early clinical studies conducted in the country for global development.
Parexel has 28 offices and 7,150 employees across the Asia Pacific region, and established operations in Korea in 2000.
Through the partnership, Parexel and CHA have recently completed a Phase I First-in-Human clinical trial at CHA's Seoul, South Korea facility.
Parexel provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the global pharmaceutical, biotechnology, and medical device industries.
The company has approximately 18,900 employees with offices in 85 locations in 52 countries.